The letter's signatories include executives at major companies, including General Motors, Eli Lilly, Lockheed Martin, General ...
When Novo Nordisk reports earnings Wednesday morning, investors will be seeking reassurance that they haven’t overestimated ...
Madrigal’s Rezdiffra has launched a new MASH market, but ‘tremendous change’ is on the horizon
With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) in March this year, Madrigal’s Rezdiffra is a pioneer in a market set for rapid change. | With the FDA ...
We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...
Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...
Only time will tell if GLP-1 drugs are headed for those fates, Palakodeti says. Novo Nordisk, the drug company that makes ...
The FDA became aware of the problem after a patient submitted a complaint to the regulator that a vial of semaglutide from Fullerton Wellness had an unidentified "black particulate" floating in it.
VK2735 is a dual GLP-1/GIP receptor agonist similar to Eli Lilly's (LLY) blockbuster weight loss drug Zepbound, designed to ...
As of Oct. 31, the price/fair value metric of the US stock market was 1.02, representing a 2% premium to our fair value ...
The Danish drugmaker plans to introduce a combination drug, CagriSema, that could result in 25% weight loss — higher than ...
As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ramped up legal actions against its competitors. | As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ...
In other news: a Kansas prisoner sues over health care; the FDA warns against contaminated compounded weight loss drugs; bird flu; tuberculosis; and more.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback